Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 5/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 7/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13954947 | 0.80 | AURKB (0.47) | AURKBAURKAMAPKAPK5PTK6FLT3 | |
| SCHEMBL13845492 | 0.75 | AURKA (0.57) | AURKBAURKAFLT3TTK | |
| SCHEMBL13954831 | 0.74 | AURKA (0.51) | AURKBAURKAFLT3 | |
| SCHEMBL2402248 | 0.73 | MAPKAPK5 (0.51) | AURKBAURKAMAPKAPK5PTK6FLT3 | |
| SCHEMBL10169418 | 0.73 | MAPKAPK5 (0.51) | AURKBAURKAMAPKAPK5PTK6FLT3 | |
| SCHEMBL13954834 | 0.69 | MAPKAPK5 (0.46) | AURKBAURKAMAPKAPK5PTK6LCK | |
| SCHEMBL14536960 | 0.68 | MAPKAPK5 (0.62) | AURKBAURKAMAPKAPK5PTK6TTK | |
| SCHEMBL30138985 | 0.68 | MAPKAPK5 (0.62) | AURKBAURKAMAPKAPK5PTK6FLT3 | |
| SCHEMBL13955032 | 0.68 | AURKB (0.51) | AURKBAURKAPTK6FLT3LCK | |
| SCHEMBL12473053 | 0.68 | AURKB (0.54) | AURKBAURKAMAPKAPK5PTK6FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |